NASDAQ:ONC - Nasdaq - US07725L1026 - ADR - Currency: USD
230.98
+2.84 (+1.24%)
The current stock price of ONC is 230.98 USD. In the past month the price decreased by -12.04%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.09 | 306.02B | ||
AMGN | AMGEN INC | 13.99 | 149.08B | ||
GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
ARGX | ARGENX SE - ADR | 318.82 | 36.23B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
NTRA | NATERA INC | N/A | 20.02B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
BIIB | BIOGEN INC | 7.2 | 17.36B | ||
INSM | INSMED INC | N/A | 13.21B |
Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The firm has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The firm has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. The company also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
BEIGENE LTD-ADR
c/o Mourant Governance Services (Cayman), 94 Solaris Avenue, Camana Bay
George Town BEIJING KY
Employees: 10473
Company Website: https://www.beigene.com/
Investor Relations: https://ir.beigene.com
Phone: 13459494123
The current stock price of ONC is 230.98 USD. The price increased by 1.24% in the last trading session.
The exchange symbol of BEIGENE LTD-ADR is ONC and it is listed on the Nasdaq exchange.
ONC stock is listed on the Nasdaq exchange.
12 analysts have analysed ONC and the average price target is 281.37 USD. This implies a price increase of 21.82% is expected in the next year compared to the current price of 230.98. Check the BEIGENE LTD-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BEIGENE LTD-ADR (ONC) has a market capitalization of 24.88B USD. This makes ONC a Large Cap stock.
BEIGENE LTD-ADR (ONC) currently has 10473 employees.
BEIGENE LTD-ADR (ONC) has a support level at 230.74 and a resistance level at 242.76. Check the full technical report for a detailed analysis of ONC support and resistance levels.
The Revenue of BEIGENE LTD-ADR (ONC) is expected to grow by 35.78% in the next year. Check the estimates tab for more information on the ONC EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ONC does not pay a dividend.
BEIGENE LTD-ADR (ONC) will report earnings on 2025-05-01.
BEIGENE LTD-ADR (ONC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.33).
The outstanding short interest for BEIGENE LTD-ADR (ONC) is 31.58% of its float. Check the ownership tab for more information on the ONC short interest.
ChartMill assigns a technical rating of 2 / 10 to ONC.
ChartMill assigns a fundamental rating of 3 / 10 to ONC. ONC may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ONC reported a non-GAAP Earnings per Share(EPS) of -6.33. The EPS increased by 21.52% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -15.97% | ||
ROE | -26.99% | ||
Debt/Equity | 0.31 |
ChartMill assigns a Buy % Consensus number of 82% to ONC. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 109.55% and a revenue growth 35.78% for ONC